Accelerating SLC Transporter Research: Streamlining Knowledge and Validated Tools.
作者信息
Wiedmer Tabea, Ingles-Prieto Alvaro, Goldmann Ulrich, Steppan Claire M, Superti-Furga Giulio
机构信息
CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.
Pfizer Worldwide Research, Development & Medical, Groton, Connecticut, USA.
出版信息
Clin Pharmacol Ther. 2022 Sep;112(3):439-442. doi: 10.1002/cpt.2639. Epub 2022 Aug 8.
Abstract
摘要
相似文献
1
Accelerating SLC Transporter Research: Streamlining Knowledge and Validated Tools.
Clin Pharmacol Ther. 2022 Sep;112(3):439-442. doi: 10.1002/cpt.2639. Epub 2022 Aug 8.
2
A guide to plasma membrane solute carrier proteins.
FEBS J. 2021 May;288(9):2784-2835. doi: 10.1111/febs.15531. Epub 2020 Sep 18.
3
The genetic landscape of the human solute carrier (SLC) transporter superfamily.
Hum Genet. 2019 Dec;138(11-12):1359-1377. doi: 10.1007/s00439-019-02081-x. Epub 2019 Nov 2.
4
Systematic in silico discovery of novel solute carrier-like proteins from proteomes.
PLoS One. 2022 Jul 28;17(7):e0271062. doi: 10.1371/journal.pone.0271062. eCollection 2022.
5
Rational exploration of fold atlas for human solute carrier proteins.
Structure. 2022 Sep 1;30(9):1321-1330.e5. doi: 10.1016/j.str.2022.05.015. Epub 2022 Jun 13.
6
Establishment of a novel microscale thermophoresis ligand-binding assay for characterization of SLC solute carriers using oligopeptide transporter PepT1 (SLC15 family) as a model system.
J Pharmacol Toxicol Methods. 2018 Jul-Aug;92:67-76. doi: 10.1016/j.vascn.2018.03.004. Epub 2018 Mar 23.
7
Targeting Solute Carrier Transporters through Functional Mapping.
Trends Pharmacol Sci. 2021 Jan;42(1):3-6. doi: 10.1016/j.tips.2020.11.005. Epub 2020 Nov 21.
8
Exploiting Cysteine Residues of SLC Membrane Transporters as Targets for Drugs.
SLAS Discov. 2019 Oct;24(9):867-881. doi: 10.1177/2472555219856601. Epub 2019 Jun 28.
9
Solute Carrier Transporters as Potential Targets for the Treatment of Metabolic Disease.
Pharmacol Rev. 2020 Jan;72(1):343-379. doi: 10.1124/pr.118.015735.
10
The ABCs of membrane transporters in health and disease (SLC series): introduction.
Mol Aspects Med. 2013 Apr-Jun;34(2-3):95-107. doi: 10.1016/j.mam.2012.12.009.
引用本文的文献
1
Data- and knowledge-derived functional landscape of human solute carriers.
Mol Syst Biol. 2025 May 12. doi: 10.1038/s44320-025-00108-2.
2
The growing research toolbox for SLC13A5 citrate transporter disorder: a rare disease with animal models, cell lines, an ongoing Natural History Study and an engaged patient advocacy organization.
Ther Adv Rare Dis. 2024 Jul 31;5:26330040241263972. doi: 10.1177/26330040241263972. eCollection 2024 Jan-Dec.
3
Advancing drug discovery through assay development: a survey of tool compounds within the human solute carrier superfamily.
Front Pharmacol. 2024 Jul 9;15:1401599. doi: 10.3389/fphar.2024.1401599. eCollection 2024.
4
Metabolic gene function discovery platform GeneMAP identifies SLC25A48 as necessary for mitochondrial choline import.
Nat Genet. 2024 Aug;56(8):1614-1623. doi: 10.1038/s41588-024-01827-2. Epub 2024 Jul 8.
5
ProteoMutaMetrics: machine learning approaches for solute carrier family 6 mutation pathogenicity prediction.
RSC Adv. 2024 Apr 22;14(19):13083-13094. doi: 10.1039/d4ra00748d.
6
Future opportunities in solute carrier structural biology.
Nat Struct Mol Biol. 2024 Apr;31(4):587-590. doi: 10.1038/s41594-024-01271-0. Epub 2024 Apr 18.
7
Membrane transporters in cell physiology, cancer metabolism and drug response.
Dis Model Mech. 2023 Nov 1;16(11). doi: 10.1242/dmm.050404. Epub 2023 Dec 1.
8
The IUPHAR/BPS Guide to PHARMACOLOGY in 2024.
Nucleic Acids Res. 2024 Jan 5;52(D1):D1438-D1449. doi: 10.1093/nar/gkad944.
本文引用的文献
1
The sequences of 150,119 genomes in the UK Biobank.
Nature. 2022 Jul;607(7920):732-740. doi: 10.1038/s41586-022-04965-x. Epub 2022 Jul 20.
2
Target 2035 - update on the quest for a probe for every protein.
RSC Med Chem. 2021 Dec 3;13(1):13-21. doi: 10.1039/d1md00228g. eCollection 2022 Jan 27.
3
MPP-Induced Changes in Cellular Impedance as a Measure for Organic Cation Transporter (SLC22A1-3) Activity and Inhibition.
Int J Mol Sci. 2022 Jan 21;23(3):1203. doi: 10.3390/ijms23031203.
4
An Overview of Cell-Based Assay Platforms for the Solute Carrier Family of Transporters.
Front Pharmacol. 2021 Aug 10;12:722889. doi: 10.3389/fphar.2021.722889. eCollection 2021.
5
Label-free high-throughput screening assay for the identification of norepinephrine transporter (NET/SLC6A2) inhibitors.
Sci Rep. 2021 Jun 10;11(1):12290. doi: 10.1038/s41598-021-91700-7.
6
Epistasis-driven identification of SLC25A51 as a regulator of human mitochondrial NAD import.
Nat Commun. 2020 Dec 1;11(1):6145. doi: 10.1038/s41467-020-19871-x.
7
The mutational constraint spectrum quantified from variation in 141,456 humans.
Nature. 2020 May;581(7809):434-443. doi: 10.1038/s41586-020-2308-7. Epub 2020 May 27.
8
The RESOLUTE consortium: unlocking SLC transporters for drug discovery.
Nat Rev Drug Discov. 2020 Jul;19(7):429-430. doi: 10.1038/d41573-020-00056-6.
9
Unexplored therapeutic opportunities in the human genome.
Nat Rev Drug Discov. 2018 May;17(5):317-332. doi: 10.1038/nrd.2018.14. Epub 2018 Mar 23.
10
SLC transporters as therapeutic targets: emerging opportunities.
Nat Rev Drug Discov. 2015 Aug;14(8):543-60. doi: 10.1038/nrd4626. Epub 2015 Jun 26.
Zotero 插件